PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-2.80%
Negative revenue growth while CRON.TO stands at 23.42%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-41.28%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
20.03%
Positive EBIT growth while CRON.TO is negative. John Neff might see a substantial edge in operational management.
20.03%
Positive operating income growth while CRON.TO is negative. John Neff might view this as a competitive edge in operations.
-89.15%
Negative net income growth while CRON.TO stands at 195.34%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-78.84%
Negative EPS growth while CRON.TO is at 195.20%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-78.84%
Negative diluted EPS growth while CRON.TO is at 195.20%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
3.24%
Share change of 3.24% while CRON.TO is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
3.24%
Diluted share change of 3.24% while CRON.TO is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
47.13%
OCF growth under 50% of CRON.TO's 564.16%. Michael Burry might suspect questionable revenue recognition or rising costs.
28.93%
FCF growth under 50% of CRON.TO's 509.54%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
-6.49%
Negative 5Y CAGR while CRON.TO stands at 216.78%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-45.05%
Negative 3Y CAGR while CRON.TO stands at 63.64%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-449.35%
Negative 10Y OCF/share CAGR while CRON.TO stands at 582.50%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
71.41%
Below 50% of CRON.TO's 151.45%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
-9039.36%
Negative 3Y OCF/share CAGR while CRON.TO stands at 135.86%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-781.73%
Negative 10Y net income/share CAGR while CRON.TO is at 313.29%. Joel Greenblatt sees a major red flag in long-term profit erosion.
68.70%
Positive 5Y CAGR while CRON.TO is negative. John Neff might view this as a strong mid-term relative advantage.
88.49%
Positive short-term CAGR while CRON.TO is negative. John Neff would see a clear advantage in near-term profit trajectory.
7068.67%
10Y equity/share CAGR above 1.5x CRON.TO's 3306.61%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-27.08%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-0.15%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.16%
Firm’s AR is declining while CRON.TO shows 0.39%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-3.39%
Inventory is declining while CRON.TO stands at 61.91%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-2.72%
Negative asset growth while CRON.TO invests at 8.53%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-4.57%
We have a declining book value while CRON.TO shows 7.15%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-9.02%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
89.29%
R&D growth drastically higher vs. CRON.TO's 29.11%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
1.66%
SG&A declining or stable vs. CRON.TO's 6.29%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.